464 studies found for:    Vaginal Diseases: Clinical Trials
Show Display Options
RSS Create an RSS feed from your search for:
Vaginal Diseases: Clinical Trials
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Safety, Acceptability and Preliminary Effectiveness of PC-515 for Vaginal Use as a Possible Microbicide
Conditions: HIV Infections;   Chlamydia Trachomatis;   Neisseria Gonorrhoeae;   Trichomonas Vaginitis;   Syphilis;   Herpes Simplex
Intervention: Drug: Carraguard (PC-515)
2 Unknown  Hyaluronic Acid and Vaginal Distress
Condition: Vaginal Disease
Intervention: Other: hyaluronic acid pill
3 Completed
Has Results
Recurrent Bacterial Vaginosis and Vaginal Acidifying Gel Trial
Condition: Bacterial Vaginosis
Interventions: Drug: Vaginal acidifying gel (RepHresh);   Drug: Metronidazole control
4 Completed Allogenic Stem Cells Derived From Lipoaspirates for the Treatment of Recto-vaginal Fistulas Associated to Crohn`s Disease (ALOREVA)
Conditions: Rectovaginal Fistula;   Crohn Disease
Intervention: Drug: Expanded allogenic adipose-derived adult stem cells
5 Completed
Has Results
A Clinical Study to Evaluate the Safety of Ospemifene
Conditions: Atrophy;   Vaginal Diseases
Interventions: Drug: Ospemifene 60 mg;   Drug: Placebo
6 Completed
Has Results
A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women
Conditions: Atrophy;   Vaginal Diseases
Interventions: Drug: Ospemifene 30 mg;   Drug: Ospemifene 60 mg;   Drug: Placebo;   Drug: Nonhormonal vaginal lubricant
7 Completed
Has Results
A Clinical Study to Evaluate the Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women
Conditions: Atrophy;   Vaginal Diseases
Interventions: Drug: Placebo;   Drug: Ospemifene 5 mg;   Drug: Ospemifene 15 mg;   Drug: Ospemifene 30 mg
8 Completed Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms
Conditions: Menopause;   Postmenopausal Vaginal Atrophy
Intervention: Drug: estradiol, 10 mcg
9 Completed Study of the Management of Vaginal Discharge in West African Using Single Dose Treatments
Conditions: Bacterial Vaginosis;   Candidiasis;   Vaginitis
Intervention: Drug: tinidazole+fluconazole vs metronidazole+clotrimazole
10 Completed Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Conditions: Advanced Adult Primary Liver Cancer;   Anaplastic Thyroid Cancer;   Bone Metastases;   Carcinoma of the Appendix;   Distal Urethral Cancer;   Fallopian Tube Cancer;   Gastrinoma;   Glucagonoma;   Inflammatory Breast Cancer;   Insulinoma;   Liver Metastases;   Localized Unresectable Adult Primary Liver Cancer;   Lung Metastases;   Male Breast Cancer;   Malignant Pericardial Effusion;   Malignant Pleural Effusion;   Metastatic Gastrointestinal Carcinoid Tumor;   Metastatic Parathyroid Cancer;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Newly Diagnosed Carcinoma of Unknown Primary;   Occult Non-small Cell Lung Cancer;   Pancreatic Polypeptide Tumor;   Primary Peritoneal Cavity Cancer;   Proximal Urethral Cancer;   Pulmonary Carcinoid Tumor;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adrenocortical Carcinoma;   Recurrent Adult Primary Liver Cancer;   Recurrent Anal Cancer;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Carcinoma of Unknown Primary;   Recurrent Cervical Cancer;   Recurrent Colon Cancer;   Recurrent Endometrial Carcinoma;   Recurrent Esophageal Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Recurrent Gastric Cancer;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Pancreatic Cancer;   Recurrent Parathyroid Cancer;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Small Intestine Cancer;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Thyroid Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Recurrent Vaginal Cancer;   Recurrent Vulvar Cancer;   Skin Metastases;   Small Intestine Adenocarcinoma;   Somatostatinoma;   Stage III Adenoid Cystic Carcinoma of the Oral Cavity;   Stage III Adrenocortical Carcinoma;   Stage III Bladder Cancer;   Stage III Cervical Cancer;   Stage III Colon Cancer;   Stage III Endometrial Carcinoma;   Stage III Esophageal Cancer;   Stage III Follicular Thyroid Cancer;   Stage III Gastric Cancer;   Stage III Malignant Testicular Germ Cell Tumor;   Stage III Mucoepidermoid Carcinoma of the Oral Cavity;   Stage III Ovarian Epithelial Cancer;   Stage III Pancreatic Cancer;   Stage III Papillary Thyroid Cancer;   Stage III Prostate Cancer;   Stage III Rectal Cancer;   Stage III Renal Cell Cancer;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Vaginal Cancer;   Stage III Vulvar Cancer;   Stage IIIA Anal Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Anal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IV Adrenocortical Carcinoma;   Stage IV Anal Cancer;   Stage IV Bladder Cancer;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Endometrial Carcinoma;   Stage IV Esophageal Cancer;   Stage IV Follicular Thyroid Cancer;   Stage IV Gastric Cancer;   Stage IV Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Pancreatic Cancer;   Stage IV Papillary Thyroid Cancer;   Stage IV Prostate Cancer;   Stage IV Rectal Cancer;   Stage IV Renal Cell Cancer;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Cervical Cancer;   Stage IVA Vaginal Cancer;   Stage IVB Cervical Cancer;   Stage IVB Vaginal Cancer;   Stage IVB Vulvar Cancer;   Thyroid Gland Medullary Carcinoma;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer;   Urethral Cancer Associated With Invasive Bladder Cancer;   WDHA Syndrome
Interventions: Biological: recombinant interleukin-12;   Biological: ABI-007/carboplatin/trastuzumab
11 Completed
Has Results
Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity
Conditions: Atrophy;   Vaginal Diseases
Interventions: Drug: Ospemifene 60 mg;   Drug: Placebo;   Drug: Non-hormonal vaginal lubricant
12 Completed
Has Results
Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus
Conditions: Atrophy;   Vaginal Diseases
Interventions: Drug: Ospemifene (Dose 1);   Drug: Ospemifene (Dose 2);   Drug: Placebo
13 Completed
Has Results
Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus
Conditions: Atrophy;   Vaginal Diseases
Intervention: Drug: Ospemifene
14 Completed Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Atrophic Vaginitis: An Extension Trial
Conditions: Menopause;   Postmenopausal Vaginal Atrophy
Intervention: Drug: estradiol, 25 mcg
15 Completed Safety, Acceptability and Preliminary Effectiveness of Carraguard™ (PC-515) in Preventing HIV/STI Transmission
Conditions: HIV Infections;   Chlamydia Trachomatis;   Neisseria Gonorrhoeae;   Trichomonas Vaginitis;   Syphilis
Intervention: Drug: Carraguard (PC-515)
16 Unknown  Trial of Male Circumcision: HIV, Sexually Transmitted Disease (STD) and Behavioral Effects in Men, Women and the Community
Conditions: HIV Infections;   Sexually Transmitted Diseases;   Papillomavirus Infections;   Genital Herpes;   Gonorrhea;   Chlamydia Infections;   Syphilis;   Bacterial Vaginosis
Intervention: Procedure: Male circumcision
17 Terminated
Has Results
A Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis
Condition: Atrophic Vaginitis
Interventions: Drug: Estriol;   Drug: Estradiol valerate;   Drug: Vanicream Lite
18 Unknown  Lcr35® for Bacterial Vaginosis Prevention
Condition: Bacterial Vaginosis
Interventions: Drug: placebo;   Drug: Lcr35®
19 Completed Prevention of Very Preterm Delivery by Testing for and Treatment of Bacterial Vaginosis
Condition: Pregnancy
Interventions: Drug: Clindamycin;   Drug: Placebo
20 Completed Bacterial Vaginosis; A Randomized Trial to Reduce Recurrence
Condition: Bacterial Vaginosis
Interventions: Other: hygienic information plus 62% ethyl alcohol in emollient gel;   Other: hygienic information

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years